Bharat Biotech, IVI launch Chikungunya Vaccine Phase 2/3 trial in Costa Rica

CEPI first partnered with IVI and Bharat Biotech in June 2020, providing up to USD 14.1 million for vaccine manufacturing and clinical development of the BBV87 vaccine candidate.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

by Alison A. Bettis, Ma ïna L’Azou Jackson, In-Kyu Yoon, J. Gabrielle Breugelmans, Ana Goios, Duane J. Gubler, Ann M. Powers Chikungunya fever is an acute febrile illness that is often associated with severe polyarthralgia in humans. The disease is caused by chikungunya virus (CHIKV), a mosquito-borne alphavirus. Since its reemergence in 2004, the virus has spread throughout the tropical world and several subtropical ar eas affecting millions of people to become a global public health issue. Given the significant disease burden, there is a need for medical countermeasures and several vaccine candidates are in c...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Acta Trop. 2021 Dec 31:106300. doi: 10.1016/j.actatropica.2021.106300. Online ahead of print.ABSTRACTMost of the patients infected with Chikungunya virus (CHIKV) develop chronic manifestations characterized by pain and deformity in joints, impacting their quality of life. The aminoadamantanes, in their turn, have been exploited due to their biological activities, with amantadine and memantine recently described with anti-CHIKV activities. Here we evaluated the antiviral activity of rimantadine hydrochloride (rtdH), a well-known antiviral agent against influenza A, its platinum complex (Pt-rtd), and the precursor cis-[PtCl2...
Source: Acta Tropica - Category: Infectious Diseases Authors: Source Type: research
Conclusions/SignificanceInsecticide to prevent chikungunya and dengue in Columbia could generate significant health benefits and be cost-effective. Because of limits on diagnostic accuracy and vaccine efficacy, the cost of dengue testing and vaccination must decrease dramatically for such vaccination to be cost-effective in Colombia. The vectors for chikungunya and dengue have recently spread to new regions, highlighting the importance of understanding the effectiveness and cost-effectiveness of policies aimed at preventing these diseases.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
sto Pérez-Rueda Reverse vaccinology is an outstanding strategy to identify antigens with high potential for vaccine development. Different parameters of five prediction programs were used to assess their sensitivity and specificity to identify B-cell epitopes of Chikungunya virus (CHIKV) strains reported in the IEDB database. The results, based on the use of 15 to 20 mer epitopes and the polyproteins to which they belong, were compared to establish the best parameters to optimize the prediction of antigenic peptides of the Mexican strain CHIKV AJV21562.1. LBtope showed the highest specificity when we used the re...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
This article discusses 5 infections causing significant morbidity and mortality across Asia, Latin America, and Africa. Avian influenza and the Middle East respiratory syndrome are highly contagious zoonoses spread through aerosol and droplets, affecting predominantly Asia. Dengue infection and chikungunya are endemic mosquito-borne viruses in tropical regions across Asia, Latin America, and Africa. Ebola is a highly contagious virus spread through human-to-human contact. The latest information in clinical manifestations, infection, prevention control, chemoprophylaxis, vaccination, and public health measures is reviewed.
Source: Pediatric Clinics of North America - Category: Pediatrics Authors: Source Type: research
Condition:   Chikungunya Virus Interventions:   Biological: CHIKV VLP/adjuvant;   Biological: Placebo Sponsor:   Emergent BioSolutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chikungunya Virus Interventions:   Biological: CHIKV VLP/adjuvant;   Biological: Placebo Sponsor:   Emergent BioSolutions Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chikungunya Virus Interventions:   Biological: CHIKV VLP/adjuvant;   Biological: Placebo Sponsor:   Emergent BioSolutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Faster vaccine development could be a step closer thanks to £ 4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer ™ . Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Announcements, Business and Enterprise, Grants and Awards, Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty Source Type: news
More News: Biotechnology | Chikungunya | Costa Rica Health | Pharmaceuticals | Vaccines